Responsibilities

• Own and drive the U.S. brand strategy, including pre-launch planning, positioning, value narrative, and long-range plan for Navtemadlin.
• Lead the end-to-end U.S. launch strategy and integrated launch plan, translating strategic choices into clear workstreams, milestones, accountabilities, and decision points.
• Ensure a single, differentiated, and scientifically credible brand narrative across customer segments, channels, and cross-functional partners.
• Lead scenario planning for key clinical, regulatory, competitive, access, and operational uncertainties, and drive timely mitigation and course correction.
• Build a lifecycle strategy that anticipates future evidence, indications, combinations, customer needs, and competitive developments.
• Develop and execute a comprehensive market-shaping strategy to build disease awareness, clarify the patient journey, strengthen diagnostic and referral pathways, and prepare the market for launch.
• Identify and prioritize the stakeholders, institutions, care settings, and treatment decision points that will most influence launch success.
• Generate actionable insights from hematologists/oncologists, patients, caregivers, advocacy organizations, payers, health systems, and other relevant stakeholders.
• Partner with Medical Affairs and Market Access to address evidence, education, access, and adoption barriers within appropriate functional and compliance boundaries.
• Define the commercial model for an oral therapy, including customer engagement, patient identification, treatment initiation, adherence, persistence, distribution, access, and support considerations.

Requirements

• 15+ years of progressive commercial pharmaceutical or biotechnology experience, including senior U.S. marketing or brand leadership roles.
• Deep hematology/oncology experience, with a strong understanding of treatment pathways, specialist customers, centers of care, and the competitive dynamics of hematology space.
• Proven success leading or playing a central leadership role in a U.S. product launch, from pre-launch strategy and readiness through launch execution and optimization.
• Demonstrated experience commercializing oral drugs, including the distinct customer, patient journey, access, distribution, initiation, adherence, and persistence considerations associated with oral therapies.
• Proven market-shaping experience, including disease education, patient journey development, stakeholder activation, diagnostic/referral pathway enhancement, or creation of a new treatment category.
• Demonstrated track record of owning brand strategy and business performance and achieving financial, strategic, and launch objectives.
• Strong scientific and clinical acumen, with the ability to translate complex evidence into clear commercial strategy and customer value propositions.
• Demonstrated ability to lead cross-functionally, influence senior stakeholders, manage ambiguity, and make high-quality decisions in a matrixed environment.
• Experience leading and developing high-performing teams and agency partners.
• Strong understanding of U.S. pharmaceutical promotional, regulatory, legal, and compliance requirements.

Preferred

• Direct leadership of a successful oncology or hematology launch in the U.S., preferably involving a first-in-class therapy, novel mechanism, or significant market-development component.
• Experience leading commercialization strategy for therapies requiring substantial stakeholder activation, treatment paradigm evolution, or market creation
• Experience in a market requiring significant pre-launch education, treatment pathway evolution, or new stakeholder behaviors.

Benefits

• Ipsen also provides parental leave, paid time off, a discretionary winter shutdown, well-being allowance, commuter benefits, and much more.